Category: Disclosures

[Disclosure] Hyundai Motor (005380) – Future Business and Management Plan (Fair Disclosure) / 2024-08-28

August 28, 2024August 12, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hyundai Motor announced its mid-to-long-term ‘Hyundai Way’ strategy and Value-up Program, planning approximately KRW 120.5T in investments over a 10-year period from 2024 to 2033. 📊 [Key Disclosure Contents & Major Figures Summary] (Note: These figures represent forward-looking plans and are subject to change based on…

Disclosures, Automotive

[Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Presentation / 2024-08-28

August 28, 2024August 1, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The company will participate in IR group meetings in Seoul sponsored by Citi Group and JPMorgan for major overseas institutional investors. Key discussion topics include rising demand for high-spec HBM TC Bonders, expansion into the 2.5D packaging (CoWoS) market, and potential TC Bonder applications in AI…

Disclosures, Semiconductors

[Disclosure] Hanwha Ocean (042660) – Other Management Matters (Voluntary Disclosure) (Correction) / 2024-08-28

August 28, 2024August 9, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary This filing discloses an amendment to Hanwha Ocean’s business acquisition of the plant business from Hanwha Corporation, modifying the net asset settlement timing terms from “within 2 months from closing” to “within 2 months from closing or on a date separately agreed upon by the parties.”…

Disclosures, Shipbuilding

[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in Europe (Part 1 & 2) (Rheumatoid Arthritis) / 2024-08-27

August 27, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan (Part 1 & Part 2) to the European Medicines Agency (EMA) to evaluate the efficacy and safety of CT-P13 SC (Zymfentra) in patients with rheumatoid arthritis. 📊 [Key Disclosure Details…

Disclosures, Bio & Healthcare

[Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Presentation / 2024-08-26

August 26, 2024August 1, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary The company will participate in the ‘UBS Korea Summit’ sponsored by UBS Securities in Seoul for major overseas institutional investors. Key discussion topics include a review of Q2 2024 results, H2 performance outlook, continued rise in AI chip demand, and potential new demand for TC Bonders…

Semiconductors, Disclosures

[Disclosure] Celltrion (068270) – Final Marketing Authorization Granted by European Commission (EC) for Steqeyma (CT-P43, Stelara Biosimilar) / 2024-08-26

August 26, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has received final marketing authorization from the European Commission (EC) for Steqeyma (CT-P43), a biosimilar to Stelara, covering 30 European countries for indications including plaque psoriasis and Crohn’s disease. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P51 (Keytruda Biosimilar) in Europe (Part 1 & 2) / 2024-08-23

August 23, 2024August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion announced that it has submitted an application for a global Phase 3 clinical trial plan (Part 1 & Part 2) to the European Medicines Agency (EMA) to evaluate the efficacy and safety of CT-P51 compared with Keytruda in patients with non-small cell lung cancer. 📊…

Disclosures, Bio & Healthcare

[Disclosure] Hanwha Ocean (042660) – Sales and Supply Contract / 2024-08-23

August 23, 2024August 9, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary This filing discloses Hanwha Ocean’s contract win valued at KRW 460.2B to construct one military support ship for the Defense Acquisition Program Administration (DAPA). 📊 [Key Disclosure Highlights & Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Contract Execution and Monitoring Further Adjustments This filing represents…

Disclosures, Shipbuilding

[Disclosure] Hanwha Aerospace (012450) – Trading Suspension and Resumption / 2024-08-22

August 22, 2024August 10, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Trading for Hanwha Aerospace common stock will be suspended from August 29, 2024, until its re-listing date due to electronic registration changes and cancellations stemming from its corporate spin-off. 📊 [Key Disclosure Details & Summary of Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Trading…

Disclosures, Defense

[Disclosure] Hanwha Aerospace (012450) – Trading Suspension and Resumption of Stock Futures and Options / 2024-08-22

August 22, 2024August 10, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Following the trading halt on the underlying common stock, trading for Hanwha Aerospace’s stock futures and options will be suspended starting August 29, 2024. 📊 [Key Disclosure Details & Summary of Figures] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring Underlying Asset Trading Resumption and Derivatives…

Disclosures, Defense